Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.10, read 2026-11-03
Ethical does not pass the values gate
Price69.22 USD
Fair value110.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup52.65+31.5% to today ✓Distribution gives way to Markup after a 6% slide in 9 days
2026-10-02Read Distribution55.97+23.7% to today Markup gives way to Distribution first Distribution read since July
2026-08-05Read Markup58.30+18.7% to today ✓Distribution gives way to Markup after a 6% slide in 5 weeks
2026-07-02Read Distribution62.28+11.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Maximus, Inc. holds its Markup at $69.22. The statistical read favours the buyers, held for 7 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 7 days
Price at the screen
$69.22
Valuation
10.30 trailing · 8.19 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.55
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
35.49%
Below 33%
Interest-bearing debt is 35.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
23.17%
Below 49%
Money owed to the company is 23.2% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Maximus,'s business is in a permissible area, but its interest-bearing debt is about 35% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MMS's ethical verdict changes
Today MMS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 38% discount to our $110.00 fair value.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 37.1% discount to the base estimate.
Where our models see it going: fair-value estimate $110.00, with a range of $110.00 to $137.02, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Government contractor shows cheap numbers but we pass
Picture a firm handling benefit claims and eligibility checks for governments. Revenue is already sliding four percent, yet the shares trade at just six point four times forward earnings with a twenty two percent return on equity. The ethical screen clears it, but the opportunity rating stays at none because falling top line growth and an unknown moat outweigh the apparent value.
We pass because a low multiple on declining sales often signals more than a bargain. Two analysts see a target near one hundred five dollars against our own fair value of one hundred sixteen dollars, yet none of that shifts the call when the business itself is shrinking.
Risk sits in execution on government contracts and any further revenue pressure that could compress margins from the current seven percent level. Currency or policy shifts abroad add another layer. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MMS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$63.72+2.7%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it none, with a mean price target of $105. Insiders have been net sellers over the past quarter.
2026-10-25Markup$62.07+6.9%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it none, with a mean price target of $105. Insiders have been net sellers over the past quarter.
2026-10-18Markup$58.08+10.3%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it none, with a mean price target of $105. Insiders have been net sellers over the past quarter.
2026-10-11Markup · changed$52.65-5.9%Entry 7
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it none, with a mean price target of $105. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it none, with a mean price target of $105.
2026-09-05Markup$58.97+1.1%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it none, with a mean price target of $105.
2026-08-05Markup · changed$58.30-6.4%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 6.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it none, with a mean price target of $105.
2026-07-18Distribution$62.28+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it none, with a mean price target of $105.
2026-07-03Distribution$62.28+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$62.28Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
